Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Roivant Sciences Ltd. Common Shares (ROIV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Roivant Sciences Ltd. Common Shares — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.81 (market cap $8.88B), while Roivant Sciences Ltd. Common Shares trades at $33.9 (market cap $24.99B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 2.8× Kymera Therapeutics Inc. Common Stock's market cap, and Roivant Sciences Ltd. Common Shares is more actively traded (4,711,562 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Roivant Sciences Ltd. Common Shares for 3 Days on average.
| KYMR | ROIV | |
|---|---|---|
Market Cap | $8.88B | $24.99B |
Volume | 1,028,790 | 4,711,562 |
Sector | Health | Health |
52-Week High | $127.31 | $41.81 |
52-Week Low | $55.80 | $16.99 |
Typical Hold Time | 0 Days | 3 Days |
Enterprise Value | $8.27B | $21.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Roivant Sciences (ROIV) trades at $33.35, down 3.58% on the day amid a bearish technical signal. The stock faces fundamental headwinds with a net loss of $172 million in 2025 and negative cash flow, though recent news highlights pipeline progress including positive Phase 2 data for mosliciguat in PH-ILD. Analyst sentiment remains strongly bullish with a consensus price target of $46.75.
The outlook hinges on clinical execution; upside exists if pipeline assets like LISRAYA launch successfully, but high cash burn and profitability challenges pose significant risks. Near-term price action is pressured, but long-term value depends on converting R&D into commercial success.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Roivant Sciences Ltd. Common Shares
Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →
